Although eosinophilic inflammation is characteristic of asthma pathogenesis, neutrophilic
inflammation is also marked, and eosinophils and neutrophils can coexist in some cases …

Phosphodiesterase4 inhibitors are currently under development for the treatment of
respiratory diseases including asthma and chronic obstructive pulmonary disease. The …

The recognition that there are some patients with features of asthma and chronic obstructive
pulmonary disease (COPD) has highlighted the need to develop more specific treatments for …

Background A minority of patients with asthma have uncontrolled or partially controlled
asthma despite intensive treatment. These patients present a special challenge because of …

Current therapy for asthma with inhaled corticosteroids and long-acting inhaled β 2-agonists
is highly effective, safe and relatively inexpensive, but for many patients, their disease …

Effective treatment of severe asthma is a major unmet need because patients' symptoms are
not controlled on maximum treatment with inhaled therapy. Asthma symptoms can be poorly …

Asthma is a chronic inflammatory disease that affects about 300 million people worldwide, a
total that is expected to rise to about 400 million over the next 15–20 years. Most asthmatic …

Noneosinophilic airway inflammation occurs in approximately 50% of patients with asthma. It
is subdivided into neutrophilic or paucigranulocytic inflammation, although the proportion of …

Phosphodiesterases (PDEs) are a family of enzymes which catalyse the metabolism of the
intracellular cyclic nucleotides, c-AMP and c-GMP that are expressed in a variety of cell …

Increased neutrophils are a feature of airway inflammation in patients with chronic
obstructive pulmonary disease and in some patients with asthma, particularly patients with …